+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Novolog Or Novomix Or NovoRapid Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • PDF Icon

    Report

  • 175 Pages
  • April 2025
  • Region: Global
  • The Business Research Company
  • ID: 6103962
The novolog or novomix or novorapid market research report is one of a series of new reports that provides novolog or novomix or novorapid market statistics, including novolog or novomix or novorapid industry global market size, regional shares, competitors with an novolog or novomix or novorapid market share, detailed novolog or novomix or novorapid market segments, market trends, and opportunities, and any further data you may need to thrive in the novolog or novomix or novorapid industry. This novolog or novomix or novorapid research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to increasing preference for rapid-acting insulin, increasing adoption of insulin delivery devices, rising awareness about diabetes control, expansion of healthcare infrastructure, and growing prevalence of diabetes. Major trends in the forecast period include advancement in technology, integration of digital technologies, telemedicine and remote monitoring, continuous glucose monitoring (CGM) systems, and innovations in medical technology.

The increasing prevalence of diabetes is expected to significantly drive the growth of the Novolog, Novomix, and Novorapid market. Diabetes is a chronic condition where the body either cannot produce enough insulin or cannot effectively use it, leading to elevated blood sugar levels. The rise in diabetes cases is fueled by factors such as aging populations, higher obesity rates, more sedentary lifestyles, genetic predispositions, and changing dietary habits. As the global prevalence of diabetes continues to rise, there is an escalating demand for diabetes management solutions. Novolog, Novomix, and Novorapid provide effective treatment by delivering rapid-acting insulin, which helps lower blood sugar quickly, and, in the case of Novomix, a combination of both rapid- and intermediate-acting insulin for immediate and sustained control. This approach simplifies diabetes management, enhances treatment adherence, and improves blood sugar stability and health outcomes. According to the World Health Organization in November 2024, nearly 450 million adults aged 30 and older had diabetes in 2022, a significant increase from previous years, with diabetes prevalence in adults growing from 7% to 14% over the past three decades. This surge in diabetes cases is driving the market for these insulin treatments.

The rise in healthcare spending is also expected to contribute to the growth of the Novolog, Novomix, and Novorapid market. Healthcare spending refers to the financial resources directed toward healthcare services, products, and infrastructure by individuals, governments, and organizations. The global increase in healthcare expenditures is driven by an aging population, a higher prevalence of chronic diseases, and the growing demand for improved healthcare systems. Novolog, Novomix, and Novorapid play a role in this spending by providing an effective solution for diabetes management through rapid-acting insulin and, in the case of Novomix, a combination for sustained glucose control. These treatments help reduce long-term complications associated with diabetes, improve overall treatment efficiency, and support better resource allocation for sustainable healthcare spending. Health Affairs reported in July 2024 that U.S. health spending is projected to grow to 19.7% of GDP by 2032, up from 17.3% in 2022, with national health expenditures expected to increase by 7.5% in 2023. This rising healthcare spending is positively impacting the market for Novolog, Novomix, and Novorapid.

The growing geriatric population is another factor expected to drive the growth of the Novolog, Novomix, and Novorapid market. The geriatric population, typically defined as people aged 65 and older, is increasing due to longer life expectancies, declining birth rates, advancements in healthcare, and improved living standards. Older adults are more likely to experience age-related health issues, including diabetes and other chronic conditions, which increases the demand for effective diabetes management solutions. Novolog, Novomix, and Novorapid are beneficial for this demographic by providing insulin therapy that helps regulate blood sugar levels, address age-related metabolic changes, reduce the risk of diabetes-related complications, and improve overall health and quality of life. According to the World Health Organization in October 2024, it is projected that by 2030, one in six people globally will be aged 60 or older, and by 2050, the number of people in this age group will double to 2.1 billion. This demographic shift is contributing to the growing demand for insulin treatments, driving the market for Novolog, Novomix, and Novorapid.

The key company operating in the novolog or novomix or novorapid market is Novo Nordisk A/S.

North America was the largest region in the novolog or novomix or novorapid market in 2024. The regions covered in novolog or novomix or novorapid report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the novolog or novomix or novorapid market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Novolog, Novomix, and Novorapid are insulin formulations designed to help manage blood sugar levels in individuals with diabetes. These products replicate the body’s natural insulin response, aiding in the absorption of glucose from the bloodstream into the cells.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indications for Novolog, Novomix, and Novorapid are type 1 and type 2 diabetes. Type 1 diabetes is a chronic condition where the immune system erroneously attacks and destroys the insulin-producing beta cells in the pancreas, resulting in elevated blood sugar levels. This form of diabetes typically develops in children and young adults. The insulin formulations are available in various forms, including vials, pre-filled pens, and cartridges. They are distributed through multiple channels, such as hospital pharmacies, retail pharmacies, and online platforms, and are used by a broad range of end-users, including both adults and the elderly.

The novolog or novomix or novorapid market consists of sales of novolog flexpen, novorapid penfill, and novomix 50. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Novolog Or Novomix Or NovoRapid Market Characteristics
3. Novolog Or Novomix Or NovoRapid Market Biologic Drug Characteristics
3.1. Molecule Type
3.2. Route Of Administration (ROA)
3.3. Mechanism Of Action (MOA)
3.4. Safety And Efficacy
4. Novolog Or Novomix Or NovoRapid Market Trends And Strategies5. Novolog Or Novomix Or NovoRapid Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
6. Global Novolog Or Novomix Or NovoRapid Growth Analysis And Strategic Analysis Framework
6.1. Global Novolog Or Novomix Or NovoRapid PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis Of End Use Industries
6.3. Global Novolog Or Novomix Or NovoRapid Market Growth Rate Analysis
6.4. Global Novolog Or Novomix Or NovoRapid Historic Market Size and Growth, 2019 - 2024, Value ($ Million)
6.5. Global Novolog Or Novomix Or NovoRapid Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Million)
6.6. Global Novolog Or Novomix Or NovoRapid Total Addressable Market (TAM)
7. Global Novolog Or Novomix Or NovoRapid Pricing Analysis & Forecasts
8. Novolog Or Novomix Or NovoRapid Market Segmentation
8.1. Global Novolog Or Novomix Or NovoRapid Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Type 1 Diabetes
  • Type 2 Diabetes
8.2. Global Novolog Or Novomix Or NovoRapid Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Vials
  • Pre-filled Pens
  • Cartridges
8.3. Global Novolog Or Novomix Or NovoRapid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
8.4. Global Novolog Or Novomix Or NovoRapid Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Adult
  • Geriatric
9. Global Novolog Or Novomix Or NovoRapid Epidemiology Of Clinical Indications
9.1. Drug Side Effects
9.2. Incidence And Prevalence of Clinical Indications
10. Novolog Or Novomix Or NovoRapid Market Regional And Country Analysis
10.1. Global Novolog Or Novomix Or NovoRapid Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
10.2. Global Novolog Or Novomix Or NovoRapid Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
11. Asia-Pacific Novolog Or Novomix Or NovoRapid Market
11.1. Asia-Pacific Novolog Or Novomix Or NovoRapid Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Novolog Or Novomix Or NovoRapid Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
11.3. Asia-Pacific Novolog Or Novomix Or NovoRapid Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
11.4. Asia-Pacific Novolog Or Novomix Or NovoRapid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
12. China Novolog Or Novomix Or NovoRapid Market
12.1. China Novolog Or Novomix Or NovoRapid Market Overview
12.2. China Novolog Or Novomix Or NovoRapid Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
12.3. China Novolog Or Novomix Or NovoRapid Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
12.4. China Novolog Or Novomix Or NovoRapid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
13. India Novolog Or Novomix Or NovoRapid Market
13.1. India Novolog Or Novomix Or NovoRapid Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
13.2. India Novolog Or Novomix Or NovoRapid Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
13.3. India Novolog Or Novomix Or NovoRapid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
14. Japan Novolog Or Novomix Or NovoRapid Market
14.1. Japan Novolog Or Novomix Or NovoRapid Market Overview
14.2. Japan Novolog Or Novomix Or NovoRapid Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
14.3. Japan Novolog Or Novomix Or NovoRapid Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
14.4. Japan Novolog Or Novomix Or NovoRapid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
15. Australia Novolog Or Novomix Or NovoRapid Market
15.1. Australia Novolog Or Novomix Or NovoRapid Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
15.2. Australia Novolog Or Novomix Or NovoRapid Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
15.3. Australia Novolog Or Novomix Or NovoRapid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
16. South Korea Novolog Or Novomix Or NovoRapid Market
16.1. South Korea Novolog Or Novomix Or NovoRapid Market Overview
16.2. South Korea Novolog Or Novomix Or NovoRapid Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
16.3. South Korea Novolog Or Novomix Or NovoRapid Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
16.4. South Korea Novolog Or Novomix Or NovoRapid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
17. Western Europe Novolog Or Novomix Or NovoRapid Market
17.1. Western Europe Novolog Or Novomix Or NovoRapid Market Overview
17.2. Western Europe Novolog Or Novomix Or NovoRapid Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
17.3. Western Europe Novolog Or Novomix Or NovoRapid Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
17.4. Western Europe Novolog Or Novomix Or NovoRapid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
18. UK Novolog Or Novomix Or NovoRapid Market
18.1. UK Novolog Or Novomix Or NovoRapid Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
18.2. UK Novolog Or Novomix Or NovoRapid Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
18.3. UK Novolog Or Novomix Or NovoRapid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
19. Germany Novolog Or Novomix Or NovoRapid Market
19.1. Germany Novolog Or Novomix Or NovoRapid Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
19.2. Germany Novolog Or Novomix Or NovoRapid Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
19.3. Germany Novolog Or Novomix Or NovoRapid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
20. France Novolog Or Novomix Or NovoRapid Market
20.1. France Novolog Or Novomix Or NovoRapid Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
20.2. France Novolog Or Novomix Or NovoRapid Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
20.3. France Novolog Or Novomix Or NovoRapid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
21. Eastern Europe Novolog Or Novomix Or NovoRapid Market
21.1. Eastern Europe Novolog Or Novomix Or NovoRapid Market Overview
21.2. Eastern Europe Novolog Or Novomix Or NovoRapid Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
21.3. Eastern Europe Novolog Or Novomix Or NovoRapid Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
21.4. Eastern Europe Novolog Or Novomix Or NovoRapid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
22. North America Novolog Or Novomix Or NovoRapid Market
22.1. North America Novolog Or Novomix Or NovoRapid Market Overview
22.2. North America Novolog Or Novomix Or NovoRapid Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
22.3. North America Novolog Or Novomix Or NovoRapid Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
22.4. North America Novolog Or Novomix Or NovoRapid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
23. USA Novolog Or Novomix Or NovoRapid Market
23.1. USA Novolog Or Novomix Or NovoRapid Market Overview
23.2. USA Novolog Or Novomix Or NovoRapid Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
23.3. USA Novolog Or Novomix Or NovoRapid Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
23.4. USA Novolog Or Novomix Or NovoRapid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
24. Canada Novolog Or Novomix Or NovoRapid Market
24.1. Canada Novolog Or Novomix Or NovoRapid Market Overview
24.2. Canada Novolog Or Novomix Or NovoRapid Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
24.3. Canada Novolog Or Novomix Or NovoRapid Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
24.4. Canada Novolog Or Novomix Or NovoRapid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
25. South America Novolog Or Novomix Or NovoRapid Market
25.1. South America Novolog Or Novomix Or NovoRapid Market Overview
25.2. South America Novolog Or Novomix Or NovoRapid Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
25.3. South America Novolog Or Novomix Or NovoRapid Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
25.4. South America Novolog Or Novomix Or NovoRapid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
26. Middle East Novolog Or Novomix Or NovoRapid Market
26.1. Middle East Novolog Or Novomix Or NovoRapid Market Overview
26.2. Middle East Novolog Or Novomix Or NovoRapid Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
26.3. Middle East Novolog Or Novomix Or NovoRapid Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
26.4. Middle East Novolog Or Novomix Or NovoRapid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
27. Africa Novolog Or Novomix Or NovoRapid Market
27.1. Africa Novolog Or Novomix Or NovoRapid Market Overview
27.2. Africa Novolog Or Novomix Or NovoRapid Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
27.3. Africa Novolog Or Novomix Or NovoRapid Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
27.4. Africa Novolog Or Novomix Or NovoRapid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
28. Novolog Or Novomix Or NovoRapid Market Competitive Landscape And Company Profiles
28.1. Novolog Or Novomix Or NovoRapid Market Competitive Landscape
28.2. Novolog Or Novomix Or NovoRapid Market Company Profiles
28.2.1. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
29. Global Novolog Or Novomix Or NovoRapid Market Pipeline Analysis
29.1. High Level Clinic Trail Information
30. Global Novolog Or Novomix Or NovoRapid Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Novolog Or Novomix Or NovoRapid Market32. Recent Developments In The Novolog Or Novomix Or NovoRapid Market
33. Novolog Or Novomix Or NovoRapid Market High Potential Countries, Segments and Strategies
33.1 Novolog Or Novomix Or NovoRapid Market In 2029 - Countries Offering Most New Opportunities
33.2 Novolog Or Novomix Or NovoRapid Market In 2029 - Segments Offering Most New Opportunities
33.3 Novolog Or Novomix Or NovoRapid Market In 2029 - Growth Strategies
33.3.1 Market Trend Based Strategies
33.3.2 Competitor Strategies
34. Appendix
34.1. Abbreviations
34.2. Currencies
34.3. Historic And Forecast Inflation Rates
34.4. Research Inquiries
34.5. About the Analyst
34.6. Copyright And Disclaimer

Executive Summary

Novolog Or Novomix Or NovoRapid Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on novolog or novomix or novorapid market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase:

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Description

Where is the largest and fastest growing market for novolog or novomix or novorapid ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The novolog or novomix or novorapid market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Indication: Type 1 Diabetes; Type 2 Diabetes
2) By Formulation: Vials; Pre-filled Pens; Cartridges
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End User: Adult; Geriatric

Key Companies Profiled: Novo Nordisk A/S

Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery Format: PDF, Word and Excel Data Dashboard.

Companies Mentioned

  • Novo Nordisk A/S